CRISPR causes serious DNA damage with high frequency – but it’s often overlooked
By Claire Robinson,
GMWatch
| 08. 09. 2023
The latest in a long series of papers has been published, detailing unintended effects of CRISPR gene editing. The new review summarises the many types of serious unintended on-target (at the intended edit site) DNA damage resulting from CRISPR/Cas gene editing.
The review appears as the European Commission and the UK government maintain their pretence that gene editing is a precise, predictable, and controllable technique and that food plants made with this technology are therefore as safe as those produced by conventional breeding.
The authors of the new paper, from Rice University in the US, reviewed the literature on CRISPR gene editing in human, primate, and mouse cells. They found that CRISPR-induced double-strand breaks in the DNA caused numerous large unintended on-target genetic damages, including large and small deletions and insertions, and chromosomal rearrangements of genetic material. And they note that even large on-target gene modifications are not detectable by standard methods.
Because the unintended effects of CRISPR gene editing highlighted in the new review are on-target mutations at the intended edit site, improving the targeting of the editing tool...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...